Journal
NEUROSCIENCE LETTERS
Volume 332, Issue 2, Pages 127-130Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/S0304-3940(02)00936-9
Keywords
amyloid-beta; noladin ether; anandamide; cannabinoid; mitogen activated protein kinase; neurons; Alzheimer's; corticotrophin-releasing hormone
Categories
Ask authors/readers for more resources
Cannabinoid receptor agonists including anandamide and noladin ether have recently been suggested to exhibit neuroprotective properties. The amyloid-beta (Abeta) peptide is thought to be responsible for the neurodegenerative changes associated with Alzheimer's disease pathology. This study characterizes the effects of anandamide and noladin ether on the neurotoxicity of Abeta in differentiated human teratocarcinoma cell line, Ntera 2/cl-D1 neurons. Anandamide and noladin ether, at nanomolar concentrations, showed concentration dependent inhibition of Abeta toxicity. A CB1 cannabinoid receptor antagonist, AM251, prevented the protective effects of anandamide and noladin ether. The mitogen activated protein kinase (MAPK) pathway inhibitor PD98059 also prevented the protective effects of cannabinoids and corticotrophin-releasing hormone. These results suggest that activation of the MAPK pathway by either cannabinoids or corticotrophin-releasing hormone could be used to prevent Abeta peptide induced neurodegeneration. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available